Laser companies set to battle for angina market
This article was originally published in Clinica
The number of transmyocardial revascularisation (TMR) devices on the US market doubled last week when the FDA approved the Eclipse Surgical Technologies' holmium laser-based system. The prompt final approval came after the device won strong backing from the FDA review panel in October 1998, for its effectiveness in reducing angina pain in patients with severe coronary artery disease (see Clinica No 832, p 15). The company's share price rose 21% to $13.625 on the day of the announcement.